For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink:https://www.kuickresearch.com/report-cd-antigen-cancer-therapy-market-outlook-and-clinical-trials-insight-2023.php
Table of Contents
1. Introduction to CD Antigen Based Cancer Therapeutics
1.1 Prologue to CD Antigens
1.2 Background: Discovering CD Antigens in Cancer Therapy
1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics
2. Significance of CD Antigens: Normal Cells versus Cancer Cells
2.1 CD Antigens in Normal Cells
2.2 CD Antigens in Cancer
3. Working Mechanism of CD Antigen Based Cancer Therapeutics
4. Commercial Cancer Therapeutics Based on CD Antigens
4.1 Monoclonal Antibodies
4.2 Antibody Drug Conjugates
4.3 Bispecific Antibodies
5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics
5.1 CAR-T Cell Therapy
5.2 Aptamers
5.3 Immunoconjugates
5.3.1 Radio Immunoconjugate
5.3.2 Toxin Immunoconjugate
5.4 Novel CD Antigen Based Antibodies
5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)
5.4.2 DART and TandAb
6. Major CD Antigens as Targets for Cancer Therapy
6.1 CD20
6.2 CD19
6.3 CD137
6.4 CD38
6.5 CD70
6.6 CD22
6.7 CD30
6.8 CD33
6.9 CD37
7. Major CD Antigens as Cancer Diagnostic Agents
7.1 CD20
7.2 CD5
7.3 CD56
7.4 CD66e
7.5 CD15
7.6 CD30
7.7 CD3
8. Major CD Antigens in Cancer Research
8.1 CD34
8.2 CD10
8.3 CD26
8.4 CD117
8.5 CD44
8.6 CD57
9. Global CD Antigen Based Therapeutics Market Overview
9.1 Market Progression
9.2 Current Market Scenario
9.3 Global CD Antigen Based Cancer Therapeutics Market Trends
9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview
10. Price and Dosage Analysis of Major CD Antigen Based Cancer Therapies
10.1 Rituximab (CD20)
10.2 Ofatumumab (CD20)
10.3 Obinutuzumab (CD20)
10.4 Daratumumab (CD38)
10.5 Brentuximab Vedotin (CD30)
10.6 Gemtuzumab Ozogamicin (CD33)
10.7 Inotuzumab Ozogamicin (CD22)
10.8 Ibritumomab Tiuxetan (CD20)
10.9 Blinatumomab (CD19, CD3)
10.10 Tisagenlecleucel (CD19)
11. Marketed Cancer CD Antigen Inhibitors Clinical and Patent Insight
11.1 Rituximab (MabThera and Rituxan)
11.2 Obinutuzumab (Gazyva and Gazyvaro)
11.3 Ibritumomab Tiuxetan (Zevalin and Zevamab)
11.4 Rituximab Biosimilar (AcellBia and USMAL)
11.5 Rituximab Biosimilar (Reditux and Tidecron)
11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima and Tuxella)
11.7 Rituximab Biosimilar (Novex)
11.8 Rituximab Biosimilar (RituxiRel, Toritz and Toritz RA)
11.9 Rituximab Biosimilar (Maball)
11.10 Rituximab Biosimilar (Kikuzubam)
11.11 Rituximab Biosimilar (Mabtas)
11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat and Remniq)
11.13 Avelumab (BAVENCIO)
11.14 Pembrolizumab (Keytruda)
11.15 Atezolizumab (TECENTRIQ)
11.16 Durvalumab (Imfinzi)
11.17 Rituximab Biosimilar (Zytux)
12. Global CD Antigen Cancer Therapy Market Dynamics
12.1 Market Growth Drivers
12.1.1 Large Patient Base
12.1.2 Unmet Medical Need
12.1.3 Better Safety Profile
12.1.4 Accelerated Research and Development: Newly Identified CD Antigens in Cancer
12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market
12.1.6 Strong Clinical Pipeline
12.2 CD Antigen Market Challenges
12.2.1 High Prices of CD Antigen Based Cancer Therapeutics
12.2.2 Difficulties in Differentiating CD Target on Cancer Cells
12.2.3 High Production Cost Due to Complex Structure
13. Global CD Antigens Cancer Therapy Market Future Forecast
14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
15. Cancer CD 3 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-II
16. Cancer CD 4 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
16.1 Phase-I
17. Cancer CD 7 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
17.1 Preclinical
18. Cancer CD 19 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
18.1 Phase-I
18.2 Phase-I/II
18.3 Phase-II
18.4 Phase-III
19. Cancer CD 20 Antigen Inhibiors Clinical Pipeline by Company, Indication and Phase
19.1 Unknown
19.2 Research
19.3 Preclinical
19.4 Clinical
19.5 Phase-I
19.6 Phase-I/II
19.7 Phase-II
19.8 Phase-III
19.9 Registered
20. Cancer CD 22 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
20.1 Preclinical
20.2 Phase-III
20.3 Registered
21. Cancer CD 26 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
21.1 Preclinical
21.2 Phase-I/II
22. Cancer CD 27 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
22.1 Research
22.2 Preclinical
22.3 Phase-II
23. Cancer CD 30 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
23.1 Phase-I
24. Cancer CD 33 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
24.1 Phase-I
24.2 Phase-I/II
25. Cancer CD 38 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
25.1 Research
25.2 Preclinical
25.3 Phase-I/II
25.4 Phase-III
26. Cancer CD 44 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
26.1 Preclinical
26.2 Phase-I
27. Cancer CD 45 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
27.1 Phase-III
28. Cancer CD 46 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
28.1 Research
29. Cancer CD 47 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II
30. Cancer CD 52 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
30.1 Research
30.2 Preclinical
31. Cancer CD 55 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
31.1 Preclinical
31.2 Phase-II
32. Cancer CD 56 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
32.1 Phase-II
33. Cancer CD 66 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
33.1 Phase-I
34. Cancer CD 70 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
34.1 Phase-II
35. Cancer CD 71 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
35.1 Preclinical
36. Cancer CD 98 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
36.1 Phase-I
37. Cancer CD 200 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
37.1 Preclinical
37.2 Clinical
37.3 Phase-II
38. Cancer CD 223 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
38.1 Preclinical
38.2 Phase-I
38.3 Phase-I/II
38.4 Phase-II
39. Cancer CD 248 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
39.1 Preclinical
39.2 Phase-II
40. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
40.1 Research
40.2 Preclinical
40.3 Clinical
40.4 Phase-I
40.5 Phase-I/II
41. Cancer CD 319 Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
41.1 Phase-I
42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication and Phase
42.1 Preclinical
42.2 Phase-I
42.3 Phase-I/II
43. Competitive Landscape
43.1 AryoGen Biopharma
43.2 Biocad
43.3 Biogen Idec
43.4 Celltrion
43.5 Genentech
43.6 Genmab
43.7 GLYCART Biotechnology
43.8 Hetero Drugs
43.9 mAbxience
43.10 MedImmune
43.11 Merck
43.12 Sandoz
43.13 UCB
Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy
Figure 2 1: CD Antigens as Markers on Normal Leukocytes
Figure 2 2: Significance of CD Antigen in Cancer Cell and its Inhibition by Therapeutic Antibody
Figure 4-1: Types of CD Antigen Based Cancer Therapeutics
Figure 4-2: Structure of Monoclonal Antibody
Figure 4-3: Types of Therapeutic Monoclonal Antibodies
Figure 4-4: Architecture of Antibody Drug Conjugates
Figure 4-5: Bispecific Antibody Structure
Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies
Figure 5-2: Structure of Radio Immunoconjugate
Figure 5-3: Structure of Bispecific T-Cell Engager Antibody
Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody
Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab
Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin
Figure 9-1: Global – Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017
Figure 9-2: Global – CD20 Cancer Therapeutic Segmentation by Region (%), 2017
Figure 9-3: Global – Rituximab Sales (US$ Billion), 2013-2016
Figure 9-4: Global – Ofatumumab Sales (US$ Million), 2013-2016
Figure 9-5: Global – Obinutuzumab Sales (US$ Million), 2015 and 2016
Figure 9-6: Global – Ibritumomab Tiuxetan Sales (US$ Million), 2013-2016
Figure 9-7: Global – Daratumumab Sales (US$ Million), 2015-2017*
Figure 9-8: Global – Daratumumab Half Yearly Sales (US$ Million), 2016 and 2017
Figure 9-9: Global – Brentuximab Vedotin Sales (US$ Million), 2014-2017
Figure 9-10: Global – Blinatumomab Sales (US$ Million), 2015-2017*
Figure 9-11: Global – Blinatumomab Sales (US$ Million), 2015-2017
Figure 9-12: Global – Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-13: Global – Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-14: Global – Cancer CD 3 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-15: Global – Cancer CD 3 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-16: Global – Cancer CD 19 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-17: Global – Cancer CD 19 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-18: Global – Cancer CD 20 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-19: Global – Cancer CD 20 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-20: Global – Cancer CD 22 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-21: Global – Cancer CD 22 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-22: Global – Cancer CD 26 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-23: Global – Cancer CD 26 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-24: Global – Cancer CD 27 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-25: Global – Cancer CD 27 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-26: Global – Cancer CD 33 Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-27: Global – Cancer CD 33 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-28: Global – Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-29: Global – Cancer CD 38 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-30: Global – Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-31: Global – Cancer CD 44 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-32: Global – Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-33: Global – Cancer CD 47 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-34: Global – Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-35: Global – Cancer CD 52 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-36: Global – Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-37: Global – Cancer CD 55 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-38: Global – Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-39: Global – Cancer CD 200 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-40: Global – Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-41: Global – Cancer CD 223 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-42: Global – Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-43: Global – Cancer CD 248 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-44: Global – Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-45: Global – Cancer CD 274 Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-46: Global – Cancer CD Miltiple Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-47: Global – Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017
Figure 9-48: Global – Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-49: Global – Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 10-1: US – Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2017
Figure 10-2: US – Rituximab Vial Price by Quantity (US$), 2017
Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US$), 2017
Figure 10-4: US – Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-5: US – Ofatumumab Vial Price by Quantity (US$), 2017
Figure 10-6: Ofatumumab – Treatment Dosage Analysis (mg)
Figure 10-7: Ofatumumab – Price Analysis by Dosage (US$)
Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)
Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)
Figure 10-10: US – Obinituzumab Solution Price (US$), 2017
Figure 10-11: Obinutuzumab – Therapy First Cycle Average Cost (US$), 2017
Figure 10-12: Obinutuzumab Average Treatment Cost (US$), 2017
Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)
Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)
Figure 10-15: US – Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US$), 2017
Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US$), 2017
Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US$), 2017
Figure 10-19: US – Brentuximab Vedotin Price Analysis, (US$), 2017
Figure 10-20: US – Brentuximab Vedotin Treatment Expenditure (US$), 2014
Figure 10-21: US – Brentuximab Vedotin Treatment Cost (US$), 2017
Figure 10-22: Global – Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US$), 2010 and 2017
Figure 10-23: US – Ibritumomab Tiuxetan Product and Dose Price Analysis (US$), 2017
Figure 10-24: US – Blinatumomab Dosage Average Price Analysis (US$), 2017
Figure 10-25: US – Blinatumomab Treatment First Cycle Average Cost (US$), 2017
Figure 10-26: US – Blinatumomab Treatment Subsequent Cycle Average Cost (US$), 2017
Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors
Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate
Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges
